InpharmD vs Andson Biotech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Andson Biotech leads in AI visibility (41 vs 26)

InpharmD

EmergingHealthcare

General

AI drug information platform with clinical pharmacist review for healthcare providers; $6.5M seed from 645 Ventures and YC competing with UpToDate for complex drug interaction and dosing guidance.

AI VisibilityBeta
Overall Score
D26
Category Rank
#562 of 1158
AI Consensus
68%
Trend
up
Per Platform
ChatGPT
28
Perplexity
31
Gemini
17

About

InpharmD is an Atlanta-based healthcare technology company providing AI-assisted drug information and clinical pharmacist intelligence to healthcare providers — enabling physicians, nurses, and clinical staff to get evidence-based answers to complex drug questions (drug interactions, off-label use guidance, dosing in special populations, emerging therapies) through an AI platform that combines clinical pharmacist review with database-backed pharmaceutical intelligence. Founded in 2018 and a Y Combinator W21 graduate, InpharmD raised $6.63 million total including a $6.5 million seed round in December 2023 led by 645 Ventures with participation from Qlarant Capital and Atlanta Ventures.

Full profile

Andson Biotech

EmergingHealthcare

General

Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.

AI VisibilityBeta
Overall Score
C41
Category Rank
#220 of 1158
AI Consensus
62%
Trend
up
Per Platform
ChatGPT
49
Perplexity
36
Gemini
40

About

Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.

Full profile

AI Visibility Head-to-Head

26
Overall Score
41
#562
Category Rank
#220
68
AI Consensus
62
up
Trend
up
28
ChatGPT
49
31
Perplexity
36
17
Gemini
40
28
Claude
41
26
Grok
51

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.